about
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective ...
Read More
2.93
-0.24
(-7.57%)
1.4M
XNAS Volume
High vol.+loss this week
XNAS 12 Sep, 2025 4:11 PM (EDT)
Board Meeting
The next board meeting for Lite Strategy Inc. is on 19 Sep 2025 for the purpose of MEI Pharma Inc Annual Report for 2025
See details
Not Eligible
Expensive Valuation
Technically Neutral
Lite Strategy Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..